Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000178772 | SCV000230926 | uncertain significance | not provided | 2018-08-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000178772 | SCV001684862 | likely benign | not provided | 2024-10-14 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000178772 | SCV001714678 | uncertain significance | not provided | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002478593 | SCV002789851 | uncertain significance | Bilirubin, serum level of, quantitative trait locus 1; Crigler-Najjar syndrome type 1; Lucey-Driscoll syndrome; Crigler-Najjar syndrome, type II; Gilbert syndrome | 2022-05-06 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004737281 | SCV005367191 | uncertain significance | UGT1A1-related disorder | 2024-09-24 | no assertion criteria provided | clinical testing | The UGT1A1 c.1352C>T variant is predicted to result in the amino acid substitution p.Pro451Leu. This variant has been reported in a patient with hereditary spherocytosis (Patient 19, Table S6, Choi et al. 2019. PubMed ID: 31122244), in combination with a second UGT1A1 variant and another variant in the ANK1 gene. It has also been reported in an infant with biliary atresia (Laochareonsuk. 2022. PubMed ID: 36350824) and an infant with severe hyperbilirubinemia (Yang. 2016. PubMed ID: 26727668). However, this variant is reported in 0.53% of alleles in individuals of East Asian descent in gnomAD, which may be too frequent to be a primary cause of disease. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |